Triple combo inhaler study for uncontrolled asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a fixed triple combination inhaler (Trimbow) for people whose asthma is not well controlled with their current treatment. It looks at how well this inhaler works in everyday life over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor-confirmed diagnosis of asthma and have been treated for it for at least 3 years.
- You are 18 or older and managed as an outpatient.
- Your asthma is still not well controlled despite using a high-dose inhaled steroid with a long-acting bronchodilator, or a triple therapy inhaler for at least 3 months.
- You meet specific criteria: had at least 1 flare-up needing oral or IV steroids in the last year, have an Asthma Control Test (ACT) score of 15 or less, and have a lung function (FEV1) below 80%.
- You have recently switched to or plan to start Trimbow 172/5/9 inhaler within 1 week of joining the study.
- You are not using long-term oral steroids (more than 5 mg prednisolone per day) or continuous oxygen, have not used biologic asthma treatments in the past year, and do not have tuberculosis or active cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a triple-inhaler called Trimbow for people whose asthma is not well controlled despite using other inhalers. The goal is to see if switching to Trimbow helps reduce asthma attacks and improve day-to-day breathing.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This study tests if using a small smart device with your Trimbow inhaler helps you use it correctly and take it as prescribed. It is for people with asthma who already use Trimbow.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
Hear when a new Asthma Bronchiale trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.